10xBio Reveals Interim Phase 2b Trial Outcomes Indicate Enhanced Effectiveness of New Treatment in Submental Fat Reduction.

Recently, a collaborative research effort involving multiple German scientific institutions has revealed that the endothelin B receptor (ETB) plays a crucial role in controlling metabolic syndrome brought on by high-calorie diets.

Initial stage of the onCARlytics study focusing on solid cancers moves forward to explore combined therapeutic approaches.

Simvastatin, a diminutive molecular entity, functions as an HMG-CoA reductase enzyme inhibitor, which is accountable for the synthesis of cholesterol in the hepatic tissue.

Johnson & Johnson has filed a supplementary application with the FDA for the authorization of TREMFYA® (guselkumab) aimed at treating moderate to severe ulcerative colitis in adults.

Bispecific antibodies (bsAbs) possess unique advantages due to their ability to simultaneously target two distinct antigens, which helps to enhance the immune system's recognition and killing of tumor cells.

Domain Therapeutics and Chime Biologics have entered into a production deal to push forward a new CCR8-targeting antibody for use in treating cancer through immunotherapy.

Glipizide, a small yet powerful drug from Pfizer Inc., effectively combats hyperglycemia and type 2 diabetes.

Monte Rosa Therapeutics has commenced preclinical trials for its novel compound MRT-8102, a pioneering NEK7-targeted molecular glue degrader with additional capabilities of impeding the NLRP3/IL-1β signaling cascade.

In January, Jiangsu Hengrui Pharmaceuticals' Tegileridine Fumarate injection, for treating moderate to severe post-op abdominal pain, was approved in China.

Aprea Therapeutics reveals it has received FDA authorization for its investigational new drug, APR-1051, a novel WEE1 kinase blocker targeting cancers with high Cyclin E levels.

Hydrocortisone, a diminutive yet powerful molecule, is renowned for its aptitude to function as a glucocorticoid receptor (GR) agonist, thereby stimulating the GR.